imugene releases final data from phase 2 her-vaxx study
Published 2 years ago • 1.3K plays • Length 5:30Download video MP4
Download video MP3
Similar videos
-
4:45
imugene thrilled with ethics approval for phase 2 her-vaxx trial
-
5:20
imugene welcomes dosing of first patient in nextherizon phase 2 clinical trial
-
6:29
imugene finishes phase 1a monotherapy dose escalation of pd1 vaxx
-
4:03
imugene doses first patient in phase-two study of cancer vaccine
-
6:15
imugene ceo hails clinical milestone for her-vaxx cancer immunotherapy
-
3:15
imugene's her-vaxx immunotherapy treatment: explained
-
19:03
imugene steps up dosage at groundbreaking vaxinia cancer trial
-
20:11
interview with the cf33 oncolytic virus inventor - imugene (imu)
-
35:36
personalized treatment of advanced her2-negative gastric or gastroesophageal junction cancer
-
8:59
imugene officially announce their her-vaxx trial results
-
4:15
imugene to commence new phase 2 pd1-vaxx bowel cancer trial
-
4:49
imugene her-vaxx video asx: imu | an emerging leader in cancer immuno-oncology
-
2:24
her-vaxx study investigator, dr marina maglakelidze
-
5:45
dr marina maglakelidze presents her-vaxx trial data at esmo 2019
-
6:40
imugene doses first patient in vaxinia phase 1 trial
-
4:45
leslie chong's first interview following our news imugene secured two fda ind approvals
-
5:39
imugene announces clinical trial supply agreement with merck kgaa and pfizer for her-vaxx
-
6:12
imugene talks dose escalation for checkvacc's city of hope trial
-
13:15
imugene ltd (asx:imu) investor presentation 2017